About Clover Biopharmaceuticals
We are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates to address the world’s most life-threatening diseases and public health threats. Our proprietary Trimer-Tag© technology platform is a development platform for the creation of novel vaccines and biologic therapies. We have leveraged our Trimer-Tag© technology platform to become a leading COVID-19 vaccine developer and potentially one of the first companies to commercialize a protein-based COVID-19 vaccine globally.
Our Trimer-Tag© technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets. These include dozens of enveloped RNA viruses (e.g. coronaviruses, rabies, respiratory syncytial virus (RSV), influenza, human immunodeficiency virus (HIV), and Ebola) and the tumor necrosis factor (TNF) superfamily (TNFSF), which have diverse biological functions and are linked to serious diseases, such as certain cancers and autoimmune disorders.
Globally, Trimer-Tag© is the only trimerization technology platform for designing and producing recombinant, secreted, covalently-linked trimeric fusion proteins (Trimer-tagged proteins) exploiting a human-derived trimerization tag. The Trimer-tagged proteins produced by our Trimer-Tag© technology platform have high potency against trimerization－dependent disease targets and favorable safety profiles.
We have built our product pipeline by employing our proprietary Trimer-Tag© technology platform and leveraging our in-house biologics manufacturing infrastructure and capabilities.
Our product pipeline consisted of (i) six Trimer-Tag© subunit vaccine candidates, including SCB-2019 (CpG 1018/Alum), for which we are conducting SPECTRA (Study Evaluating Protective-Efficacy and Safety of Clover’s Trimeric
Recombinant Protein-based and Adjuvanted COVID-19 Vaccine), a global pivotal Phase 2/3 clinical trial, (ii) two Trimer-Tag© oncology product candidates, including SCB-313 for which we are conducting five Phase 1 clinical trials in China and Australia, and (iii) three Fc-fusion product candidates, including SCB-808, for which we are conducting a pivotal Phase 3 clinical trial in China.